The MarketWatch News Office was not included in the development of this material.
BEDMINSTER, N.J. and SINGAPORE, Dec. 17, 2020 /PRNewswire by way of COMTEX/ —
BEDMINSTER, N.J. and SINGAPORE, Dec. 17, 2020 /PRNewswire/ — Tessa Therapeutics (Tessa), a scientific-phase cell remedy business creating subsequent-technology most cancers remedies, these days declared the appointment of David McIntyre as its Chief Economic Officer.
Mr. McIntyre brings more than 25 decades of worldwide monetary, operational and authorized working experience, which include about 10 years as Chief Economic Officer of several publicly outlined and privately held entities. He joins Tessa from AVITA Clinical, Inc. (ASX: AVH, NASDAQ: RCEL), the place he served as the Main Economical Officer.
Ahead of becoming a member of AVITA Clinical, Mr. McIntyre served as a Associate with Apple Tree Companions (ATP), a multibillion-greenback lifetime science venture money and progress fairness fund. At ATP Mr. McIntyre was dependable for ATP’s health care device portfolio, jointly with different working and Board features, like performing as CFO and Head of Complex Operations at Braeburn, Inc.
“I am delighted to welcome David to Tessa’s management team,” claimed Jeffrey H. Buchalter, President and CEO of Tessa Therapeutics. “His profitable expertise as a senior government for both non-public and general public detailed organizations, and also as a existence sciences undertaking money company associate tends to make him an excellent addition to our management crew at this pivotal time in Tessa’s journey.”
Prior to ATP, Mr. McIntyre was CFO and COO at HeartWare Global, Inc. (beforehand ASX: HIN NASDAQ: HTWR) in the course of its transition from pre-clinical stage to commercialization throughout additional than 20 countries. Prior to getting into existence sciences, Mr McIntyre practiced as a senior attorney at Baker & McKenzie and KPMG specializing in corporate regulation and held various senior finance roles in multi-countrywide providers.
“The recently released information of Tessa’s Autologous remedy is really extraordinary, and Tessa’s novel Allogeneic platform shows prospective to create transformative most cancers mobile therapies,” stated Mr. Mclntyre. “I am delighted to join Tessa and I seem ahead to contributing towards bringing these therapies to clients.”
Mr. McIntyre retains a Bachelor of Economics (Accounting) from the University of Sydney (Australia), a Bachelor of Legislation from the University of Engineering, Sydney (Australia) and a Master of Enterprise Administration (Fuqua Scholar) from Duke College. He is also a Licensed Practising Accountant (CPA) and is admitted as a Lawful Practitioner of the Supreme Court docket of New South Wales (in Australia).
About Tessa Therapeutics
Tessa Therapeutics is a clinical-stage biotechnology company acquiring a portfolio of next-era mobile therapies for most cancers. It has a pipeline of therapies in clinical development for the treatment method of hematological malignancies and reliable tumors.
Tessa’s guide autologous therapy is in late-stage clinical growth for procedure of lymphomas. It has demonstrated strong scientific responses in sufferers with relapsed/refractory classical Hodgkin Lymphoma, based mostly on which it was granted the RMAT designation by the U.S. Fda and the Key designation by the EMA.
Tessa is also building a novel, differentiated, allogeneic “off-the shelf” cell remedy system, to build far more efficacious, dependable, and scalable therapies capable of targeting a broad range of cancers. A remedy making use of this system is being evaluated in an ongoing clinical trial in United States.
Tessa has its global headquarters in Singapore, where by it is also setting up its very own condition-of-the-art, commercial manufacturing facility. Tessa is at the moment environment up its United States headquarters in New Jersey.
For more details on Tessa, please go to www.tessatherapeutics.com.
Source Tessa Therapeutics
Copyright (C) 2020 PR Newswire. All legal rights reserved
The MarketWatch News Section was not involved in the generation of this content material.